图片$Merck(MRK)$ and $Bristol-Myers Squibb(BMY)$ both have their eyes on the same pie: Antibody-drug conjugates (ADCs), and both companies want to split them into chunks. According to a report by DataM Intelligence, the market size of the ADCs will reach $16.6 billion by 2030, more than triple the current size of about $5 billion.In this battle for the ADCs market, who will win the final victory? And what should investors do?What are ADCs?ADCs are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through connectors, which combine the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. The a